Analysts expect that CryoPort Inc (NASDAQ:CYRX) will post sales of $9.50 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for CryoPort’s earnings, with estimates ranging from $9.40 million to $9.65 million. CryoPort reported sales of $5.29 million during the same quarter last year, which would indicate a positive year over year growth rate of 79.6%. The firm is scheduled to announce its next quarterly earnings report on Thursday, November 14th.
On average, analysts expect that CryoPort will report full-year sales of $35.04 million for the current year, with estimates ranging from $34.50 million to $35.58 million. For the next fiscal year, analysts forecast that the company will post sales of $52.51 million, with estimates ranging from $47.50 million to $58.53 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow CryoPort.
CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Thursday, August 8th. The consumer goods maker reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $8.46 million during the quarter, compared to the consensus estimate of $7.94 million. CryoPort had a negative return on equity of 17.32% and a negative net margin of 35.71%. The business’s revenue for the quarter was up 82.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.09) EPS.
A number of research analysts have issued reports on the company. Svb Leerink restated an “outperform” rating on shares of CryoPort in a research note on Monday, July 15th. BidaskClub downgraded CryoPort from a “buy” rating to a “hold” rating in a research note on Wednesday, August 28th. Needham & Company LLC assumed coverage on CryoPort in a research note on Monday, July 1st. They issued a “buy” rating and a $22.00 price objective for the company. Leerink Swann assumed coverage on CryoPort in a research note on Monday, July 15th. They issued a “buy” rating and a $24.00 price objective for the company. Finally, B. Riley set a $26.00 price objective on CryoPort and gave the company a “buy” rating in a research note on Friday, July 19th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $24.00.
Hedge funds and other institutional investors have recently modified their holdings of the company. Axiom International Investors LLC DE purchased a new position in shares of CryoPort during the 2nd quarter valued at $1,810,000. SG Americas Securities LLC purchased a new position in shares of CryoPort during the 2nd quarter valued at $249,000. Bank of America Corp DE lifted its position in shares of CryoPort by 92.3% during the 4th quarter. Bank of America Corp DE now owns 16,037 shares of the consumer goods maker’s stock valued at $176,000 after buying an additional 7,697 shares during the last quarter. AWM Investment Company Inc. purchased a new position in shares of CryoPort during the 2nd quarter valued at $641,000. Finally, Handelsbanken Fonder AB purchased a new position in shares of CryoPort during the 2nd quarter valued at $2,933,000. 59.59% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:CYRX opened at $17.85 on Wednesday. The company has a market capitalization of $686.23 million, a PE ratio of -57.58 and a beta of 0.88. The company has a debt-to-equity ratio of 0.17, a current ratio of 17.73 and a quick ratio of 17.68. The business has a fifty day moving average price of $21.45 and a two-hundred day moving average price of $17.03. CryoPort has a 1 year low of $8.28 and a 1 year high of $25.02.
CryoPort Company Profile
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Featured Article: Dividend Reinvestment Plan (DRIP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.